BiomX Issues Statement Regarding Recent Common Stock Trading Activity
Rhea-AI Summary
BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.
BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PHGE gained 69.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.7% during that session. Argus tracked a trough of -42.4% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $11M at that time. Trading volume was exceptionally heavy at 51.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
PHGE was up 2.24% while the momentum scanner flagged peers BCTX and APLM moving up (median gain about 7.1%). This supports a broader biotechnology move rather than company-specific news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Private placement | Neutral | +3.6% | Announced $3.0M private placement to support BX011 and strategic review. |
| Dec 08 | Trial discontinuation | Negative | -36.9% | Ended BX004 Phase 2b after high adverse events and began cost cuts. |
| Nov 25 | Clinical update | Neutral | +5.4% | Provided BX004 Phase 2b safety update and pushed topline results to Q2 2026. |
| Nov 14 | Reverse stock split | Neutral | +7.5% | Announced 1-for-19 reverse stock split and share count reduction. |
| Nov 12 | Earnings and update | Negative | -1.9% | Reported Q3 2025 results with limited cash and going concern language. |
Price reactions have generally aligned with news tone, including a sharp selloff on negative BX004 discontinuation news and positive responses to financing and corporate actions.
Over the last few months, BiomX has navigated clinical, financial, and capital structure shifts. Negative news such as discontinuation of the BX004 Phase 2b trial and insolvency proceedings for an Israeli subsidiary coincided with a -36.94% drop. Corporate actions, including a 1-for-19 reverse split and a $3.0M private placement, saw modest positive reactions. Earnings and liquidity updates highlighted limited cash into Q1 2026. Today’s statement simply notes no undisclosed material developments behind unusual trading.
Market Pulse Summary
The stock surged +69.5% in the session following this news. A strong positive reaction aligns with the stock’s history of moving in step with news tone, even when events are financial or structural. Recent catalysts included a 1-for-19 reverse split and a $3.0M private placement, plus earlier volatility around BX004. However, this statement explicitly cites no new undisclosed developments, so any large upside would have reflected trading dynamics and sector strength rather than fresh company fundamentals.
AI-generated analysis. Not financial advice.
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.
The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock.
NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement. The Company does not intend to make any further comment on market speculation or trading activity.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Contacts:
BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com
FAQ
What did BiomX (PHGE) say about the January 27, 2026 unusual trading?
Did BiomX (PHGE) confirm any new business developments on January 27, 2026?
Why did BiomX (PHGE) issue the trading statement on January 27, 2026?
Will BiomX (PHGE) provide more details about the market activity after January 27, 2026?
Does the January 27, 2026 statement from BiomX (PHGE) include financial or clinical updates?
